Screening of selective histone deacetylase inhibitors by proteochemometric modeling

BackgroundHistone deacetylase (HDAC) is a novel target for the treatment of cancer and it can be classified into three classes, i.e., classes I, II, and IV. The inhibitors selectively targeting individual HDAC have been proved to be the better candidate antitumor drugs. To screen selective HDAC inhibitors, several proteochemometric (PCM) models based on different combinations of three kinds of protein descriptors, two kinds of ligand descriptors and multiplication cross-terms were constructed in our study.ResultsThe results show that structure similarity descriptors are better than sequence similarity descriptors and geometry descriptors in the leftacterization of HDACs. Furthermore, the predictive ability was not improved by introducing the cross-terms in our models. Finally, a best PCM model based on protein structure similarity descriptors and 32-dimensional general descriptors was derived (R2 = 0.9897, Qtest2 = 0.7542), which shows a powerful ability to screen selective HDAC inhibitors.ConclusionsOur best model not only predict the activities of inhibitors for each HDAC isoform, but also screen and distinguish class-selective inhibitors and even more isoform-selective inhibitors, thus it provides a potential way to discover or design novel candidate antitumor drugs with reduced side effect.

[1]  Peteris Prusis,et al.  Proteochemometric modeling of HIV protease susceptibility , 2008, BMC Bioinformatics.

[2]  Eric Verdin,et al.  Histone deacetylase HDAC8 associates with smooth muscle α‐actin and is essential for smooth muscle cell contractility , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  P. Bertrand Inside HDAC with HDAC inhibitors. , 2010, European journal of medicinal chemistry.

[4]  H. Rikiishi,et al.  Autophagic and Apoptotic Effects of HDAC Inhibitors on Cancer Cells , 2011, Journal of biomedicine & biotechnology.

[5]  Takayoshi Suzuki,et al.  Explorative study on isoform-selective histone deacetylase inhibitors. , 2009, Chemical & pharmaceutical bulletin.

[6]  Shandar Ahmad,et al.  Proteochemometric Recognition of Stable Kinase Inhibition Complexes Using Topological Autocorrelation and Support Vector Machines , 2010, J. Chem. Inf. Model..

[7]  Peteris Prusis,et al.  QSAR and proteo-chemometric analysis of the interaction of a series of organic compounds with melanocortin receptor subtypes. , 2003, Journal of medicinal chemistry.

[8]  H. Hamm,et al.  G betagamma binds histone deacetylase 5 (HDAC5) and inhibits its transcriptional co-repression activity. , 2005, The Journal of biological chemistry.

[9]  Wen‐Ming Yang,et al.  Histone Deacetylases Specifically Down-regulate p53-dependent Gene Activation* , 2000, The Journal of Biological Chemistry.

[10]  N. Bertos,et al.  Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. , 2002, Nucleic acids research.

[11]  Eric Verdin,et al.  Histone Deacetylase 7 Functions as a Key Regulator of Genes Involved in both Positive and Negative Selection of Thymocytes , 2007, Molecular and Cellular Biology.

[12]  Oliver Distler,et al.  Epigenetic modifications: novel therapeutic strategies for systemic sclerosis? , 2011, Expert review of clinical immunology.

[13]  Peteris Prusis,et al.  Improved approach for proteochemometrics modeling: application to organic compound - amine G protein-coupled receptor interactions , 2005, Bioinform..

[14]  David A. Gough,et al.  Virtual Screen for Ligands of Orphan G Protein-Coupled Receptors , 2005, J. Chem. Inf. Model..

[15]  I. Longden,et al.  EMBOSS: the European Molecular Biology Open Software Suite. , 2000, Trends in genetics : TIG.

[16]  Xi Chen,et al.  Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study , 2011, BMC Bioinformatics.

[17]  Thomas Gärtner,et al.  Ligand Prediction from Protein Sequence and Small Molecule Information Using Support Vector Machines and Fingerprint Descriptors , 2009, J. Chem. Inf. Model..

[18]  Ruixin Zhu,et al.  Investigations on Inhibitors of Hedgehog Signal Pathway: A Quantitative Structure-Activity Relationship Study , 2011, International journal of molecular sciences.

[19]  Qi Liu,et al.  Virtual Drug Screen Schema Based on Multiview Similarity Integration and Ranking Aggregation , 2012, J. Chem. Inf. Model..

[20]  Ruixin Zhu,et al.  Multi-target QSAR Study in the Analysis and Design of HIV-1 Inhibitors† , 2010 .

[21]  Abhik Seal,et al.  Docking study of HIV-1 reverse transcriptase with phytochemicals , 2011, Bioinformation.

[22]  Jarl E. S. Wikberg,et al.  Proteochemometric Modeling of Drug Resistance over the Mutational Space for Multiple HIV Protease Variants and Multiple Protease Inhibitors , 2009, J. Chem. Inf. Model..

[23]  P. Labute A widely applicable set of descriptors. , 2000, Journal of molecular graphics & modelling.

[24]  Joel R. Bock,et al.  A New Method to Estimate Ligand-Receptor Energetics* , 2002, Molecular & Cellular Proteomics.

[25]  George Karypis,et al.  Multi-Assay-Based Structure-Activity Relationship Models: Improving Structure-Activity Relationship Models by Incorporating Activity Information from Related Targets , 2009, J. Chem. Inf. Model..

[26]  Yong Eun Kim,et al.  A Structure‐Based Virtual Screening Approach toward the Discovery of Histone Deacetylase Inhibitors: Identification of Promising Zinc‐Chelating Groups , 2010, ChemMedChem.

[27]  Zhen Lu,et al.  Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer , 2007, International journal of cancer.

[28]  Jun Gao,et al.  A new protein-ligand binding sites prediction method based on the integration of protein sequence conservation information , 2011, BMC Bioinformatics.

[29]  James Bradner,et al.  Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.

[30]  P. Prusis,et al.  Proteochemometric modelling of antibody-antigen interactions using SPOT synthesised peptide arrays. , 2007, Protein engineering, design & selection : PEDS.

[31]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[32]  L. Buydens,et al.  Facilitating the application of Support Vector Regression by using a universal Pearson VII function based kernel , 2006 .

[33]  Peteris Prusis,et al.  Proteochemometric Mapping of the Interaction of Organic Compounds with Melanocortin Receptor Subtypes , 2005, Molecular Pharmacology.

[34]  O. Witt,et al.  HDAC family: What are the cancer relevant targets? , 2009, Cancer letters.

[35]  Yoshiharu Kawaguchi,et al.  MDM2–HDAC1‐mediated deacetylation of p53 is required for its degradation , 2002, The EMBO journal.

[36]  Andries Petrus Engelbrecht,et al.  Using OVA modeling to improve classification performance for large datasets , 2012, Expert Syst. Appl..

[37]  K. Fidelis,et al.  Interaction Model Based on Local Protein Substructures Generalizes to the Entire Structural Enzyme‐Ligand Space. , 2009 .

[38]  Gerard J. P. van Westen,et al.  Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets , 2011 .

[39]  Jean-Philippe Vert,et al.  Virtual screening of GPCRs: An in silico chemogenomics approach , 2008, BMC Bioinformatics.

[40]  Jun Xu,et al.  Drug-Like Index: A New Approach to Measure Drug-Like Compounds and Their Diversity. , 2001 .

[41]  Heidi E. Hamm,et al.  Gβγ Binds Histone Deacetylase 5 (HDAC5) and Inhibits Its Transcriptional Co-repression Activity* , 2005, Journal of Biological Chemistry.

[42]  Zhiwei Cao,et al.  Insight into potential toxicity mechanisms of melamine: an in silico study. , 2011, Toxicology.

[43]  Qi Kang,et al.  Comparison of Ligand-, Target Structure-, and Protein-Ligand Interaction Fingerprint-based Virtual Screening Methods , 2011 .

[44]  Ruixin Zhu,et al.  Novel Natural Inhibitors of CYP1A2 Identified by in Silico and in Vitro Screening , 2011, International journal of molecular sciences.

[45]  Laurent Schaeffer,et al.  Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression , 2005, Nature Neuroscience.

[46]  Constance L. Cepko,et al.  HDAC4 Regulates Neuronal Survival in Normal and Diseased Retinas , 2009, Science.

[47]  M. Salto‐Tellez,et al.  Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 , 2005, Cell Death and Differentiation.